Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

CCA, AIMp And NPA Statement: Decriminalisation Of Dispensing Errors
The decriminalisation of dispensing errors is an issue that has united the profession.
generic viagra online
Spine-shaped Gold Protrusions Improve The Adherence And Electrical Coupling Of Neurons With The Surface Of Micro-electronic Devices
Interfacing neurons with micro- and nano-electronic devices has been a subject of intense studies over the last decade and is used both in basic research and medical applications. The electronic devices used in such neuroelectronic hybrids are mainly planar metal electrodes and planar transistors.
News of the day
First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.
Diagnostics

National Pharmacy Association Calls For Zero Increase In RPSGB Retention Fees - UK

The NPA is asking for the RPSGB retention fee to be held at the present level, given the financial pressures on pharmacy businesses, many of which pay retention fees for their staff. Margaret Peycke, NPA External Relations Manager said: "The justification to charge RPSGB members more is unclear, especially as such a large increase in fees (40%) was made in 2008, the declared purpose of which was to provide the RPSGB with the res to create the regulatory and professional leadership bodies. In such circumstances, an uplift to fees in the region of 2.2% is inappropriate." "NPA members already coping with a challenging economic environment are not in a position to comfortably absorb such increases, bearing in mind that many employers fund their employee pharmacist and technician retention fees. The NPA has recently surveyed its members and over 80% highlighted the current burden of costs on their pharmacy business." In addition the fee set by the RPSGB is a fee which will be divided between the new regulatory body (GPhC) and the new professional leadership body (PLB) after the split which is due to occur in April 2010. The document does not indicate how the fees will be apportioned between the bodies or make mention of the fact that existing members of RPSGB who do not wish to join the new PLB do not have to and will be entitled to a refund on the unused element of the fees apportioned to the PLB. National Pharmacy Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009